A study reveals that rising vaccine coverage in children is linked to reduced antibiotic prescriptions, suggesting a shift in ...

As a medical oncologist, one of the first threats I inform new patients about during the informed consent process for cancer ...

In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as ...

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate ...